Natural DNA and RNA are written with a small alphabet: four bases (adenine, guanine, cytosine, and thymine or uracil), one or two sugars (deoxyribose or ribose), and a phosphate linker that joins the sugars into a chain. Every therapeutic or research use of nucleic acids, from an antiviral tablet to a CRISPR guide RNA, depends on this same alphabet. The catch is that natural building blocks are not always enough. They are recognized by nucleases, they trigger immune sensors, and they often carry poor drug-like properties. Modified nucleosides and nucleotides solve these problems by deliberate changes to the base, the sugar, or the phosphate, while preserving the geometry that allows them to be read by polymerases, ribosomes, or target proteins. This article explains how those modifications are classified, how they are made, how they are purified and characterized, and where they are used in modern therapeutics and research.
The two terms describe closely related molecules and are sometimes used loosely, but in synthesis and analytical work the distinction matters. A nucleoside is a base joined to a sugar through an N-glycosidic bond, and nothing more: it has no phosphate. A nucleotide is the phosphorylated form of that same molecule, carrying one (mono-), two (di-), or three (tri-) phosphate groups on the 5′-OH of the sugar. The triphosphate is the actual substrate of polymerases, the monophosphate is what most kinases handle in the cell, and the nucleoside is the form usually administered as a drug because it reaches the interior of cells and is then phosphorylated by cellular enzymes.
Modification chemistry differs at each level. Nucleoside chemistry is dominated by protection-group strategies on the sugar hydroxyls and by coupling reactions that assemble the base-sugar bond. Nucleotide chemistry adds a phosphate or a phosphate analog, often in the form of a phosphoramidite or a phosphonate that can be incorporated into a synthetic oligonucleotide. The choice of phosphorylation state also affects downstream applications: phosphoramidites are used in solid-phase oligonucleotide synthesis, monophosphates are convenient for enzymatic incorporation, and triphosphates feed directly into polymerase reactions.
Every covalent bond in a nucleoside or nucleotide is a candidate for chemistry. In practice, three regions of the molecule carry most of the useful changes, and each region solves a different set of problems. The base carries the coding information and many of the interactions with proteins, so base modifications influence base-pairing, polymerase fidelity, immune recognition, and binding to target proteins. The sugar defines the geometry, nuclease stability, and conformational preference of the backbone, so sugar modifications are central to therapeutic oligonucleotides and to antiviral prodrugs. The phosphate carries the negative charges that drive solubility and that activate the molecule for enzymatic chemistry, so phosphate modifications control stability against nucleases, cellular uptake, and pharmacokinetics.
A complete picture of a modified building block, therefore, requires knowing what was changed at each of these three sites, what synthetic route delivered that change, and what property the change was intended to address. The sections that follow organize the chemistry by site, then by synthesis, then by application, so that any specific building block can be located quickly within a broader map.
Base modifications are the oldest and most varied class of nucleoside chemistry, because the heterocyclic core offers many positions for substitution without losing Watson–Crick recognition. They are also the engine of the antiviral and anticancer nucleoside drug portfolio, since many of those drugs are simply a natural nucleoside carrying one or two small substituents on the base. Base modifications are also increasingly important in mRNA therapeutics, where pseudouridine and its derivatives have reshaped the field.
Small substituents on the base—methyl, methoxy, hydroxyl, thio, and amino groups—are enough to alter recognition by polymerases, shift base-pairing strength, and avoid host immune sensors. 5-Methylcytidine (m5C) and N6-methyladenosine (m6A) are two of the most common modifications found in natural RNA, and their synthetic counterparts are widely used as research probes and as components of modified mRNA. On the drug side, 5-methyl modification of the uracil base gave rise to thymidine analogs used in DNA therapeutics, while modifications such as 5-iodo-2′-deoxyuridine have served as radiosensitizers and as labeling tools.
Oxidized nucleobases, including 8-oxo-guanosine and its deoxy form, are widely studied as markers of oxidative DNA damage, but their synthetic analogs are also useful as standards, as stable isotope-labeled internal references, and as building blocks for damage-mapping probes. Synthetic preparation of these compounds usually starts from a properly protected sugar, installs the modified base through glycosylation, and finishes with global deprotection under carefully controlled conditions to avoid further oxidation.
Halogen substitution on the base is a small change with surprisingly large effects. 5-Bromo-2′-deoxyuridine (BrdU) and 5-iodo-2′-deoxyuridine (IdU) are classical examples: the halogen replaces a methyl group without grossly distorting the base, but the heavy atom changes stacking interactions and provides a handle for detection, photocrosslinking, and crystallographic phasing. 5-Fluoro substitution underlies an important class of antiviral and anticancer drugs, where the fluorine atom disrupts thymidylate biosynthesis or is incorporated into nucleic acids in place of uracil.
Deaza modifications replace one of the ring nitrogens of the base with carbon. 7-Deaza-adenosine and 7-deaza-guanosine change the hydrogen-bonding pattern and the topology of the major groove, which is useful when stronger or weaker base-pairing is required. Deaza bases are also central to many fluorescent nucleobase analogs and to certain polymerase substrates that misincorporate natural bases less efficiently. In synthesis, deaza bases are typically installed by glycosylation with the pre-formed heterocycle, since building the ring with a sugar already attached is often impractical.
Pseudouridine (Ψ) is a C-glycoside—the base–sugar bond is a C–C bond rather than a C–N bond—and it is the most abundant modified nucleoside in natural RNA. It improves base stacking, stabilizes certain secondary structures, and is read by the ribosome and by polymerases as if it were uridine. The therapeutic significance is large: replacement of uridine with N1-methylpseudouridine in mRNA reduces innate immune activation and increases translation efficiency, and this single change has been central to the success of modern mRNA vaccines. Related C-nucleosides such as 2-thiouridine and its methylated forms provide additional layers of control over immune recognition and translation fidelity.
Synthesis of pseudouridine is conceptually different from N-nucleoside synthesis because the C–C bond cannot be formed by simple glycosylation of an intact base. Classical routes build the heterocycle onto a sugar derivative using a C-1 sugar electrophile and a pyrimidine anion equivalent, then elaborate the ring. Modern routes start from a uracil precursor, open the ring between N1 and C2, swap the connectivity, and close the ring to give the C-linked isomer. N1-methylpseudouridine is then prepared by methylation at N1 before or after the rearrangement, depending on the route chosen.
When the base must do more than code for an amino acid—when it must report on a binding event, crosslink a target, or carry a biotin tag—larger substituents are attached to the base through a linker. Fluorescent base analogs such as 2-aminopurine, ethenoadenine, and pyrrolocytosine report on local environment and base-pairing status, and are widely used in studies of polymerase dynamics, ribosome function, and nucleic acid hybridization. Reactive base-linked groups, including haloalkyl, azidoalkyl, and alkyne-substituted bases, enable bioorthogonal click chemistry, photocrosslinking, and the controlled attachment of reporter groups to nucleic acids in vitro and ex vivo.
Synthesis of these conjugates typically couples a pre-functionalized base analog to a protected sugar, then attaches the fluorophore, biotin, or click handle through a stable linker either on the base, on a sugar hydroxyl, or on a phosphate. The resulting building blocks are often supplied as phosphoramidites, so they can be inserted at a defined position in a synthetic oligonucleotide.
Table.1 Representative Base and Base–Sugar Linkage Modifications and Their Uses.
| Modification Class | Representative Building Blocks | Primary Use |
| Methylated bases | 5-Methylcytidine, N6-methyladenosine, N1-methylpseudouridine | Reduced immune activation and improved translation in mRNA; epigenetic probes. |
| Halogenated bases | 5-Bromo-2′-deoxyuridine, 5-iodo-2′-deoxyuridine, 5-fluorouridine analogs | Detection and labeling; antiviral and anticancer nucleoside drugs. |
| Deaza bases | 7-Deaza-adenosine, 7-deaza-guanosine | Modified base-pairing and polymerase fidelity; crystallographic phasing. |
| C-linked nucleosides | Pseudouridine, 2-thiouridine, 2′-thio-2′-deoxyuridine | mRNA translation, immune evasion, secondary-structure stabilization. |
| Fluorescent / reactive bases | 2-Aminopurine, pyrrolocytosine, 5-alkynyl-2′-deoxyuridine | Hybridization probes, click chemistry, photocrosslinking. |
From pseudouridine derivatives to halogenated and fluorescent bases, our chemistry team delivers modified nucleosides tailored to your target.
The sugar ring sets the pitch of the nucleic acid helix and exposes hydroxyl groups that are the main handles for nuclease attack. Sugar modifications therefore control two of the most important practical properties of a modified building block: how well it survives in biological fluids, and how well it fits into a polymerase active site. They are the modifications most associated with antisense, siRNA, and mRNA therapeutics, and with nucleoside antivirals that must resist glycosidic-bond cleavage.
The 2′-position of ribose or deoxyribose is the single most heavily modified site in therapeutic oligonucleotides. A 2′-OH makes RNA sensitive to hydrolysis; replacing it with 2′-F, 2′-O-methyl (2′′-OMe), or 2′-O-methoxyethyl (2′′-MOE) gives nuclease resistance while preserving the A-form helical geometry required for activity. 2′-F substitution has been particularly important in siRNA, where it stabilizes the guide strand against degradation and improves binding affinity. 2′′-O-methyl and 2′′-MOE modifications are the workhorses of antisense oligonucleotides and of many gapmer designs, where a central DNA gap is flanked by modified wings. Custom oligonucleotide synthesis offerings routinely draw on a deep catalog of 2′-modified phosphoramidites, and the underlying monomers are usually prepared on a multi-hundred-gram scale before being qualified for therapeutic use.
From a synthetic standpoint, 2′-modified sugars are usually prepared by stereoselective installation of the substituent on a protected sugar, often via a 2′-keto intermediate that is reduced with the desired stereochemistry or opened with a nucleophile. Protecting-group choice matters because the 2′-substituent must survive the conditions used to install the base, the phosphoramidite, and the linker, and deprotection must be possible without loss of stereochemistry.
Restricting the sugar pucker is one of the most effective ways to lock an oligonucleotide into the geometry that a protein target prefers. Locked nucleic acid (LNA) and bridged nucleic acid (BNA) contain a methylene bridge between the 2′-oxygen and the 4′-carbon that locks the sugar in a C3′-endo pucker. This single change raises the melting temperature of a duplex by several degrees per modification, and it is widely used in antisense oligonucleotides, in PCR primers, and in fluorescent hybridization probes.
4′-substituted analogs take a different approach: they replace the 4′-CH with a heteroatom or a small substituent that biases the sugar conformation. 4′-thio substitution, in which the ring oxygen is replaced by sulfur, is the most prominent example and combines enhanced nuclease stability with a preferred A-form geometry. Related modifications are used in antiviral nucleosides where the modified sugar resists glycosidic-bond cleavage and improves intracellular activation. Synthesis of these constrained sugars is more demanding than for 2′-substituted analogs because the bridging substituent must be installed early, and protecting-group strategies are tuned to it.
When the entire sugar ring is replaced—by an acyclic linker, by a carbocycle, or by a heteroaromatic scaffold—the resulting compounds are usually called acyclic nucleoside phosphonates. Tenofovir, adefovir, and cidofovir are the most prominent examples: their phosphonate group bypasses the first phosphorylation step that limits the activity of conventional nucleoside antivirals, and their acyclic sugars make them poor host drugs for many nucleases and glycosidases. Other members of this class replace the sugar with a carbocyclic ring, mimicking the geometry of the natural sugar while removing the glycosidic oxygen that is the natural site of cleavage.
Acyclic and carbocyclic nucleosides also offer practical synthetic advantages. The sugar (or sugar-mimic) can often be assembled by well-developed carbon-chain chemistry, the base can be introduced by alkylation of the heterocycle with an alkyl halide or by Mitsunobu-type coupling, and the phosphonate can be installed at a late stage via a Michaelis–Arbuzov-type reaction. These routes are typically more robust and more scalable than glycosylation routes, which is one reason that this class dominates the oral antiviral market.
Table.2 Sugar Modifications in Therapeutic and Research Nucleosides.
| Modification | Representative Examples | Property Improved |
| 2′-F | 2′-Fluoro-2′-deoxyribose phosphoramidites | Nuclease resistance and duplex stability in siRNA guide strands. |
| 2′-O-methyl / 2′-MOE | 2′-OMe, 2′-O-methoxyethyl ribonucleoside phosphoramidites | Nuclease resistance and reduced off-target effects in antisense oligonucleotides. |
| Locked / bridged | LNA, BNA, cEt BNA | Strong duplex stabilization, improved mismatch discrimination. |
| 4′-thio and 4′-substituted | 4′-Thioribonucleosides, 4′-azanucleosides | Conformation bias, nuclease resistance, antiviral activity. |
| Acyclic phosphonate | Tenofovir, adefovir, cidofovir | Bypasses first phosphorylation, oral bioavailability, antiviral activity. |
| Carbocyclic | Abacavir, carbocyclic 2′-deoxy nucleosides | Resistance to glycosidic-bond cleavage, improved metabolic stability. |
We supply 2′-, 4′-, and acyclic-modified building blocks at milligram-to-gram scale, with full QC documentation.
The phosphate group is small in size but enormous in influence. It carries the negative charges that keep nucleotides soluble, it activates them for enzymatic chemistry, and it is the part of the molecule that nucleases and phosphatases attack first. Phosphate modifications therefore control stability against hydrolysis, cellular uptake (when the modification adds a neutral or lipophilic element), and pharmacokinetics, especially for therapeutic oligonucleotides. Three families of phosphate modifications dominate modern use, and a fourth—labels attached through the phosphate—supports detection and conjugation.
The phosphorothioate (PS) modification replaces one of the non-bridging oxygens of the phosphate with sulfur. This single substitution has profound consequences: it converts the chiral phosphate into a stereogenic P-center, dramatically increases nuclease resistance, and changes the pharmacokinetic profile by promoting plasma protein binding. Most first-generation antisense and siRNA drugs contain a phosphorothioate modification at most or all backbone positions, and the synthesis is straightforward—a standard phosphoramidite coupling followed by sulfur oxidation rather than iodine oxidation.
Phosphorothioates also offer a less obvious benefit: their resistance to nucleases allows custom oligonucleotide workflows to tolerate longer sequences and higher purities, because the failure sequences are not selectively destroyed in the deprotection and cleavage steps. Other α-phosphate analogs, including methylphosphonate, phosphoramidate, and boranophosphate modifications, add further layers of stability, hydrophobicity, or charge, and each is chosen for a specific application.
When the goal is to keep the molecule intact indefinitely, the entire phosphate linkage can be replaced. Phosphodiester linkages are replaced by phosphotriesters for prodrug approaches, by methylphosphonates for uncharged backbones, and by peptide nucleic acid (PNA) or morpholino backbones when the sugar-phosphate is removed entirely. PNA chemistry, in particular, has matured into a reliable platform for diagnostic probes, antisense research tools, and certain antisense drug candidates, because the amide backbone is essentially transparent to nucleases and proteases.
Phosphonate analogs (phosphonomethyl ethers, phosphonates) replace the bridging oxygen with a carbon, removing the natural site of nuclease attack on the linkage. They are central to acyclic nucleoside antivirals as discussed earlier, and they are now used in a growing number of oligonucleotide backbones where extra stability is required. Their synthesis usually relies on a Michaelis–Arbuzov reaction of an alkyl halide with a trialkyl phosphite, or on a Horner–Wadsworth–Emmons reaction of a stabilized phosphonate carbanion with an electrophile on the sugar.
Many modified nucleotides are not consumed by polymerases at all—they are used to label, immobilize, or crosslink nucleic acids. Biotin, fluorescent dyes, quenchers, photocleavable groups, and click-chemistry handles are most reliably introduced at the 5′-phosphate end of an oligonucleotide or at an internal position through a modified phosphoramidite. Phosphate-linked labels have the advantage of not disrupting base-pairing or duplex stability as much as large substituents on the base, and they are easier to introduce in a controlled manner.
Synthesis of these conjugates typically starts from a phosphoramidite bearing the label protected with a group that survives solid-phase synthesis but is removed during the final deprotection. Alternatively, the label can be attached post-synthetically to a 5′-amino or 5′-thiol modifier. Stable isotope labeling for tracer studies uses a similar strategy, with 13C, 15N, or 2H introduced at defined positions on the base, the sugar, or the phosphate itself.
Table.3 Common Phosphate Modifications and Their Practical Effects.
| Modification Family | Representative Examples | Effect on Properties |
| Phosphorothioate (PS) | PS linkage at one or all backbone positions | Nuclease resistance; increased plasma protein binding; chiral P-center. |
| Methylphosphonate / boranophosphate | Methylphosphonate linkages; boranophosphate linkages | Uncharged or modified backbone; nuclease resistance; altered cellular uptake. |
| Phosphonate (acyclic nucleoside) | Tenofovir, adefovir phosphonate analogs | Bypasses first phosphorylation; oral bioavailability; antiviral activity. |
| Peptide / morpholino backbone | PNA, PMO backbones | Non-hydrolyzable backbone; high affinity; resistance to nucleases and proteases. |
| Phosphate-linked labels | 5′-biotin, 5′-fluorophore, 5′-click handle | Detection, immobilization, and conjugation without disrupting base-pairing. |
We prepare modified nucleotides at research and process scales, including labeled and backbone-modified species.
The synthesis of a modified building block is shaped by where the modification sits and how stable the final molecule needs to be. Four general strategies cover almost every compound of practical interest: base–sugar coupling to assemble the nucleoside from scratch, late-stage modification of an intact nucleoside, phosphorylation to install the phosphate (or its analogs) after the nucleoside is in hand, and enzymatic or chemoenzymatic routes that use polymerases, kinases, or engineered nucleoside-modifying enzymes. Most commercial building blocks combine two or three of these.
When the modification is on the base, or when the desired base is not compatible with glycosylation chemistry on a pre-formed nucleoside, the cleanest route is to build the nucleoside from a protected sugar and a free base. The sugar is usually protected at the 5′-OH (often as a dimethoxytrityl ether) and at the 3′-OH (often as a silyl ether or as an ester), leaving a 1′-chloride, 1′-acetate, or 1′-imidazolate ready for glycosylation. The base is provided as a silylated heterocycle in the Vorbrüggen method, or as a heavy-metal salt in older Hilbert–Johnson-type couplings.
Selectivity between N1-pyrimidine / N9-purine glycosylation is the critical stereochemical decision, and the protecting-group pattern on the sugar sets the face that the base attacks. Once the glycosylation is complete, global deprotection under carefully buffered conditions reveals the modified nucleoside. This strategy is the workhorse of commercial custom synthesis of base-modified antiviral and anticancer nucleosides, and it scales well because the glycosylation step can be performed on hundreds of grams of sugar in a single batch.
When the modification is on the sugar, or when a small change is being introduced on the base (a halogen, a methyl, a thio group), late-stage modification of an intact nucleoside is often more efficient than building the nucleoside from scratch. The nucleoside is taken with its hydroxyls protected, the desired functional group is installed on the sugar or the base under conditions that tolerate the rest of the molecule, and the product is globally deprotected. This is the standard approach for 2′-modified nucleosides, where a 2′-OH or a 2′-keto is converted to 2′-F, 2′-OMe, 2′-MOE, or 2′-azido in a few steps.
The same strategy is used for tritiated, deuterated, or 13C-labeled versions of existing nucleosides, where the goal is to introduce the isotope with minimal disturbance to the molecular skeleton. Customized protecting-group schemes, careful control of stereochemistry at the modified carbon, and quantitative deprotection are the key success factors for these routes.
Phosphorylation of a modified nucleoside usually starts from the 5′-OH, which is converted to a leaving group (iodide, imidazolate, or phosphate itself), and a phosphate source is attached. The classical route phosphorylates with POCl3 in trimethyl phosphate at low temperature, hydrolyzes the intermediate trichlorophosphate, and isolates the monophosphate by ion-exchange methods. The Ludwig–Eckstein approach uses salicyl chlorophosphite as a more selective reagent that is widely used for phosphorylated nucleoside analogs.
Di- and triphosphates are built by extending a monophosphate through an activated phosphorous reagent (often a phosphoramidate or an imidazolide), or by condensation of the monophosphate with a phosphate donor using a coupling reagent such as carbonyldiimidazole. Modified phosphate analogs—phosphorothioates, phosphonates, boranophosphates—are introduced in the same phosphorylation step by replacing the phosphate source with a sulfurating agent, a phosphonate ester, or a borane reagent. Dedicated phosphorylation services specializing in nucleoside chemistry handle these reactions at scales ranging from milligrams to kilograms, with purification by ion-exchange chromatography to deliver the final nucleotide.
Enzymatic phosphorylation is an attractive alternative to chemical phosphorylation because it is highly selective and avoids strong acids, bases, and low temperatures. Nucleoside kinases, nucleoside monophosphate kinases, and nucleoside diphosphate kinases from natural sources or engineered by directed evolution can convert a modified nucleoside to its monophosphate, diphosphate, or triphosphate under mild aqueous conditions. The limitation is substrate scope: not every modified nucleoside is accepted, and not every phosphate analog (phosphorothioate, phosphonate) is incorporated cleanly.
Chemoenzymatic routes combine the strengths of both worlds. A chemical step introduces a modification that the enzyme cannot tolerate (a non-natural base, a bulky label), and an enzymatic step introduces a phosphate in a stereospecific way. A common example is the synthesis of α-thiotriphosphates (Sp and Rp diastereomers): the chemical route makes the phosphorothioate monophosphate, and a polymerase or kinase extends it to the di- and triphosphate. Polymerase-mediated incorporation is also used to make modified polynucleotides for biotechnology applications, with engineered polymerases reading modified templates and incorporating labeled or non-natural nucleotides with high fidelity.
Table.4 Synthesis Strategies for Modified Nucleosides and Nucleotides.
| Strategy | When to Use | Typical Scale and Notes |
| Base–sugar coupling | Base-modified nucleosides, C-nucleosides, unusual heterocycles | Multi-gram to multi-kilogram; protection and stereochemistry must be tightly controlled. |
| Late-stage sugar modification | 2′-, 3′-, 4′-substituted nucleosides, labeled nucleosides | Milligram to gram; protection-group schemes depend on the modification. |
| Chemical phosphorylation | Modified mono-, di-, and triphosphates, phosphonate and phosphorothioate analogs | Milligram to kilogram; ion-exchange chromatography is usually required for purification. |
| Enzymatic / chemoenzymatic | Stereospecific phosphate installation, polynucleotides with modified bases | Milligram to gram; mild conditions and excellent stereochemistry for natural-like substrates. |
From lab-scale feasibility to process R&D and scale-up, our team supports your route from milligram to multi-gram batches.
A modified nucleoside or nucleotide is rarely isolated as a single compound directly from a reaction mixture. It is almost always accompanied by closely related isomers, by-products of deprotection, residual protecting groups, and unreacted starting material, and the analytical challenge is to identify the right compound, confirm its structure, and quantify it against a defined reference standard. Three workflow themes cover most real cases: purification, structural characterization, and quality control.
The purification strategy is dictated by the polarity, the charge, and the differences between the product and its impurities. Reversed-phase chromatography handles most neutral and moderately polar modified nucleosides well, with C18 columns and acetonitrile/water gradients as a typical starting point. For more polar or charged species—modified nucleotides, phosphate-linked conjugates, sulfated analogs—ion-exchange chromatography or hydrophilic-interaction chromatography (HILIC) often gives sharper separation.
Preparative HPLC remains the workhorse for milligram-to-gram purifications, and it can be coupled with on-line MS detection to allow fraction collection triggered by the desired mass. Custom purification services combine reversed-phase, ion-exchange, and HILIC methods, and they apply orthogonal strategies (for example, ion-exchange followed by reversed-phase) when a single-pass purification cannot resolve the analyte from an isomer or a salt form. Bulk ion-exchange methods are also available for gram-to-kilogram purifications of nucleotides, where loading and elution with sodium or ammonium buffers are easily scaled.
A modified building block must be characterized enough to confirm its identity, its connectivity, and its stereochemistry. The first line of evidence is high-resolution mass spectrometry, which gives the molecular formula of the intact species and of key fragments. Routine LC-MS testing provides both retention time and mass spectra in a single injection, and it is the standard method for confirming molecular weight and detecting known impurities.
NMR is the definitive tool for connectivity and stereochemistry. Detailed 1H, 13C, 19F (for fluorinated analogs), and 31P (for phosphate-bearing species) NMR experiments establish the position of every substituent and confirm the anomeric configuration of the sugar. Two-dimensional methods (HSQC, HMBC, COSY, NOESY) are used when the connectivity is not obvious from one-dimensional spectra, which is often the case for branched, fused, or polycyclic modifications. Comprehensive structure characterization packages assemble these data into a complete structural assignment suitable for publication, regulatory filing, or technical transfer.
Once the identity is established, the modified building block must be qualified for its intended use. HPLC-based purity determination with UV or charged-aerosol detection gives the chemical purity as a peak-area percentage. For nucleotides and phosphate-linked species, ion-pair chromatography or HILIC methods are often needed to resolve the analyte from its inorganic phosphate impurities and from buffer-derived ions.
Impurity profiling identifies and quantifies the impurities that travel with the product. Process impurities (starting material, by-products, residual solvents) are tracked by LC-MS, while elemental and ionic impurities (residual metals from catalysts, sulfate or chloride from buffers) are tracked by complementary techniques. Impurity reference standard characterization generates certified reference standards for the major impurities so that downstream QC methods can be calibrated against them. Reference compound synthesis provides the authentic impurity standards when commercial sources are not available.
Table.5 Analytical Techniques Used for Modified Nucleosides and Nucleotides.
| Technique | What It Confirms | Typical Role |
| Reversed-phase HPLC / HILIC | Chemical purity, isomer separation, salt-form integrity | Routine QC, release testing, purity determination. |
| LC-MS | Molecular weight, fragmentation pattern, impurity identification | Identity confirmation and impurity profiling. |
| High-resolution MS | Molecular formula, isotope patterns | Definitive identification of unknown or unexpected species. |
| NMR (1D and 2D) | Connectivity, stereochemistry, configuration at phosphorus | Full structural characterization of new or modified molecules. |
| Ion-exchange chromatography | Nucleotide mono-, di-, and triphosphate speciation | Quantification of phosphates; counterion analysis. |
| Elemental / ICP analysis | Residual metals from catalysts | Trace elemental purity for therapeutic-grade materials. |
From structure elucidation by NMR to certified impurity standards, our analytical teams deliver the data you need.
Modified nucleosides and nucleotides sit at the center of several of the most active areas of modern therapeutics and biotechnology. The same molecule can appear in a small-molecule drug, in an antisense oligonucleotide, and in an mRNA vaccine, depending on where the modification sits and how it is delivered. The four application families below—antiviral and anticancer nucleoside drugs, oligonucleotide therapeutics, mRNA therapeutics, and diagnostic or research tools—illustrate the breadth of what a single modified building block can support.
The nucleoside drug class is the original application of base- and sugar-modified nucleosides, and it remains one of the most productive areas of small-molecule drug discovery. Antiviral nucleosides (acyclic guanosine analogs for herpesviruses, cytidine analogs for hepatitis C, deoxycytidine analogs for human immunodeficiency virus) work by being phosphorylated inside infected cells and then inhibiting viral polymerases or by being incorporated into viral genomes as chain terminators. Anticancer nucleosides follow a similar logic in tumor cells, where they inhibit ribonucleotide reductase, deplete nucleotide pools, or terminate DNA synthesis.
A typical antiviral or anticancer nucleoside today is a combination of three or four modifications: a base change that confers selectivity or polymerase recognition, a sugar change that improves stability and oral bioavailability, and a phosphonate or prodrug that improves cellular activation. The design challenge is that these modifications must work together, and the chemistry challenge is that they must be assembled without disturbing each other. Modern API synthesis teams handle this challenge by using orthogonal protecting groups, by staging the most sensitive modifications late in the synthesis, and by using chemoenzymatic steps where the chemistry cannot deliver.
Antisense oligonucleotides, siRNAs, splice-switching oligonucleotides, and aptamers all require modified nucleotides as their raw materials. The most common building blocks are 2′-modified phosphoramidites (2′-F, 2′-OMe, 2′-MOE, LNA), phosphorothioate phosphoramidites, and modified bases that improve binding affinity or reduce immune activation. These monomers are usually delivered as dry powders, with HPLC purity verified by the manufacturer, and are then coupled on solid-phase oligonucleotide synthesizers at the client or at a CDMO.
The quality of the monomer dictates the quality of the oligonucleotide. Truncated sequences, depurination, and P-center stereochemistry are all traceable to the quality of the starting monomers, so rigorous QC of the monomer—including 31P NMR for phosphoramidite integrity, ion chromatography for residual phosphate, and HPLC for chemical purity—is the foundation of oligonucleotide therapeutic manufacturing. Custom synthesis of modified phosphoramidites has therefore become a substantial service category, with many rare monomers synthesized on demand for research programs.
mRNA therapeutics (vaccines, protein-replacement therapies, gene-editing systems) rely on a defined set of modified nucleotides that improve translation and reduce innate immune activation. The classical set includes N1-methylpseudouridine (m1Ψ) in place of uridine, 5-methylcytidine in place of cytidine, and sometimes 2′-thio-2′-deoxyuridine or other minor modifications. These are incorporated by RNA polymerases into long mRNA strands by in vitro transcription, and the resulting transcripts are then formulated into lipid nanoparticles.
The supply chain for these modified nucleotides is now large, but the chemistry is demanding: each modified nucleotide must be made as a high-purity triphosphate with controlled metal content, and the in vitro transcription must accept it efficiently. Quality failures at the nucleotide level propagate directly into mRNA yield, integrity, and translation efficiency, so robust synthesis and characterization of the modified triphosphates is the first bottleneck of any mRNA therapeutic program.
Beyond therapeutics, modified nucleotides are used in PCR primers (locked nucleic acid bases for allele-specific amplification), in fluorescent hybridization probes (2-aminopurine, pyrrolocytosine), in aptamers (2′-F or 2′-OME ribonucleotides for nuclease resistance), in in situ hybridization probes (digoxigenin- or biotin-labeled nucleotides), and in next-generation sequencing library preparation (azido and alkyne bases for click chemistry, blocked nucleotides for controlled termination). Each application uses a small set of modified nucleotides tailored to its detection or function.
These reagents are typically supplied as phosphoramidites (for synthetic oligonucleotides) or as triphosphates (for enzymatic incorporation). The demand pattern is many products at small scale, which has driven the growth of a vibrant custom-synthesis ecosystem that can deliver rare modified nucleotides on multi-week timelines with full QC documentation. The same chemistry and analytical infrastructure used for therapeutic building blocks supports this ecosystem, with shorter timelines and smaller batch sizes.
Table.6 Application Families for Modified Nucleosides and Nucleotides.
| Application Family | Commonly Used Modifications | Quality Requirement |
| Antiviral / anticancer nucleoside drugs | Base-modified, sugar-modified, phosphonate prodrugs | High chemical purity; well-defined salt form; controlled residual metals. |
| Oligonucleotide therapeutics | 2′-F, 2′-OMe, 2′-MOE, LNA, PS linkage | High phosphoramidite purity; controlled P-center stereochemistry when required. |
| mRNA therapeutics | N1-methylpseudouridine, 5-methylcytidine, 2′-thio-uridine | High triphosphate purity; low metal residue; polymerase compatibility. |
| Diagnostic probes / aptamers / sequencing | Locked bases, fluorescent bases, clickable bases, biotin/dye labels | High chemical purity; correct labeling stoichiometry; reproducibility lot to lot. |
From modified phosphoramidites to N1-methylpseudouridine triphosphate, we help research and process teams source rare nucleotides.
BOC Sciences supports research and process teams working on modified nucleosides and nucleotides with a complete workflow, from feasibility chemistry through process development, scale-up, and analytical characterization. Our capabilities are built around three core service lines—custom synthesis of modified building blocks, dedicated phosphorylation and nucleotide chemistry, and orthogonal purification and analytical characterization—each of which can be engaged independently or as part of an integrated program.
The custom synthesis team handles base-modified, sugar-modified, and phosphate-modified nucleosides from feasibility through process development. Routes are designed around the target molecule's properties, including protection-group strategy, glycosylation method, phosphorylation reagent, and purification mode, and they are optimized for both yield and scalability. We support custom synthesis at milligram to multi-kilogram scale, including glycosylation chemistry, late-stage sugar modification, and the synthesis of labeled nucleosides (stable isotope, fluorescent, biotin-tagged) for tracer and diagnostic applications. Process R&D and scale-up capabilities extend laboratory routes to gram and kilogram batches with reproducible quality, supported by in-process analytics and full release characterization.
The analytical team provides the data needed to confirm identity, quantify purity, and qualify modified building blocks for downstream use. Routine methods include HPLC testing, ion-exchange chromatography, and LC-MS, complemented by MS testing for molecular weight confirmation. Combined purity determination and impurity profiling packages deliver orthogonal data that give a complete picture of what is in a sample, and impurity reference standard characterization supports QC method validation. For more challenging separations, our preparative chromatography and ion-exchange capabilities enable multi-gram purification of nucleotides and conjugated species, with documentation suitable for internal or external review.
Table.7 BOC Sciences Services Supporting Modified Nucleoside and Nucleotide Programs.
| Service Name | Description | Inquiry |
| Custom Synthesis | Custom preparation of nucleosides and nucleotides with base, sugar, or phosphate modifications, including labeled analogs, from feasibility to gram scale. | Inquiry |
| Nucleosides & Nucleotides Synthesis | Dedicated chemistry for nucleoside and nucleotide building blocks, including phosphoramidites, mono-, di-, and triphosphates, and phosphonate analogs. | Inquiry |
| Custom Oligonucleotides Synthesis | Custom oligonucleotide synthesis using modified phosphoramidites, including 2′-, 4′-, base-, and backbone-modified monomers. | Inquiry |
| Phosphorylation | Phosphorylation services for nucleosides and analogs, including phosphorothioate, phosphonate, and triphosphate preparation. | Inquiry |
| Preparative HPLC | Milligram to gram purification of modified nucleosides and nucleotides, with on-line MS triggering for fraction collection. | Inquiry |
| Purity Determination | HPLC, ion-exchange, and LC-MS purity determination with full documentation for release or publication. | Inquiry |
| Structure Characterization | NMR and high-resolution MS structure characterization of new modified building blocks, including full 2D assignment. | Inquiry |
Tell us about your target molecule, scale, and timeline. Our chemists and analysts will respond with a tailored plan and a quote.
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
